A Clinical Experience: A Cutaneous Leishmaniasis Case with Spontan Abortus Following To Meglumine Antimoniate TherapyHavva Yildiz Seçkin1*, Yalçin Bas1, Zennure Takçi1, Akgül Arici2, Sercan Sezgin1 and Çigdem Kunt Isler3
- *Corresponding Author:
- Havva Yildiz Seçkin
Gaziosmanpasa University, School of Medicine
Department of Dermatology, Tokat, Turkey
Tel: +9 0 505 750 52 16
Email: [email protected]
Received date: March 28, 2014 Accepted date: June 18, 2015 Published date: June 25, 2015
Citation: Seçkin HY, Bas Y, Arici A, Sezgin S, Kunt Isler C (2015) A Clinical Experience: A Cutaneous Leishmaniasis Case with Spontan Abortus Following To Meglumine Antimoniate Therapy. J Drug Metab Toxicol 6:183. doi: 10.4172/2157-7609.1000183
Copyright: © 2015 Seckin HY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A 27 years old female patient was diagnosed with cutaneous leishmaniasis histopathologically and received intramuscular meglumine antimoniate therapy at a dose of 20 mg/kg/day for consecutive 20 days. The base-line pretreatment complete blood count, hepatic transaminases, lipase, amylase, beta-hCG level and electrocardiogram were within normal limits. Following to the treatment-free two weeks at the control visit, the patient stated that she was 4 weeks pregnant. Gynecological follow-up was recommended to the patient but it is learned that she had spontaneous abortion one day later. We presented our experience on this case regarding possible toxicity of meglumine antimoniate treatment on fetus.